Pirtobrutinib is this non-covalent inhibitor thing that zeros in on BTK, the B-cell tyrosine kinase, which is big in mantle cell lymphoma and CLL. It’s in tablet form, comes in two sizes—50 mg and 100 mg. The usual dose is 200 mg a day.
You can get these tablets in bottles with 60 in each. It does its thing by throwing a wrench into the signaling pathways, which are all messed up in mantle cell lymphoma and CLL, causing cells to grow and multiply out of control. Being non-covalent, this inhibitor can bind and unbind from the BTK enzyme.
That means it might be more adaptable in treatment than those covalent inhibitors.
